Adipocyte exosomes induce transforming growth factor beta pathway dysregulation in hepatocytes: A novel paradigm for obesity-related liver disease

Journal of Surgical Research

Volumn 192, Issue 2, 2014, Pages 268-275

  Koeck, Emily S ^a   Iordanskaia, Tatiana ^a   Sevilla, Samantha ^a   Ferrante, Sarah C ^b,c   Hubal, Monica J ^a,b,c   Freishtat, Robert J ^a,b,c   Nadler, Evan P ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Exosomes; Factor beta; Nonalcoholic fatty liver disease; Obesity; Pediatric surgery; Transforming growth

Indexed keywords

ALPHAVBETA5 INTEGRIN; ALPHAVBETA8 INTEGRIN; FLUORESCENT DYE; GELATINASE B; MATRILYSIN; MICRORNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTOR; SMAD3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; INTEGRIN; INTEGRIN ALPHAVBETA8; MMP7 PROTEIN, HUMAN; SERPINE1 PROTEIN, HUMAN; SMAD3 PROTEIN, HUMAN; TIMP1 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE-4; TRANSFORMING GROWTH FACTOR BETA1; VITRONECTIN RECEPTOR;

ADIPOCYTE; ADOLESCENT; ARTICLE; CELLULAR DISTRIBUTION; CHOLECYSTECTOMY; CLINICAL ARTICLE; CONTROLLED STUDY; EXOSOME; EXPOSURE; FEMALE; GENE EXPRESSION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; INCUBATION TIME; INTRAABDOMINAL FAT; LAPAROSCOPIC SURGERY; LIVER CELL; MORBID OBESITY; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SLEEVE GASTRECTOMY; STELLATE CELL; METABOLISM; OBESITY; PATHOLOGY; PHYSIOLOGY;

ADIPOCYTES; ADOLESCENT; EXOSOMES; FEMALE; HEP G2 CELLS; HEPATIC STELLATE CELLS; HEPATOCYTES; HUMANS; INTEGRINS; INTRA-ABDOMINAL FAT; MATRIX METALLOPROTEINASE 7; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, VITRONECTIN; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84912102867     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2014.06.050     Document Type: Article

References (50)

1. Giorgio V, Prono F, Graziano F, Nobili V. Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatr 2013;13:40.
2. Day CP, Saksena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol 2002;17(Suppl 3): S377.
3. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008;48(Suppl 1):S104.
4. Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb 2011;18:629.
5. Fuentes L, Roszer T, Ricote M. Inflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophages. Mediators Inflamm 2010;2010: 219583.
6. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev 2010;11:11.
7. Suganami T, Ogawa Y. Adipose tissue macrophages: their role in adipose tissue remodeling. J Leukoc Biol 2010;88:33.
8. de Heredia FP, Gómez-Martínez S, Marcos A. Obesity, inflammation and the immune system. Proc Nutr Soc 2012; 71:332.
9. Schäffler A, Schölmerich J. Innate immunity and adipose tissue biology. Trends Immunol 2010;31:228.
10. Smith SR, Lovejoy JC, Greenway F, et al. Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolism 2001;50:425.
11. Dâmaso AR, do Prado WL, de Piano A, et al. Relationship between nonalcoholic fatty liver disease prevalence and visceral fat in obese adolescents. Dig Liver Dis 2008;40:132.
12. Lee Y, El Andaloussi S, Wood MJ. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet 2012;21:R125.
13. EL Andaloussi S, Mäger I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 2013;12:347.
14. Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002;2:569.
15. Harding CV, Heuser JE, Stahl PD. Exosomes: looking back three decades and into the future. J Cell Biol 2013;200:367.
16. Bang C, Thum T. Exosomes: new players in cell-cell communication. Int J Biochem Cell Biol 2012;44:2060.
17. Takata A, Otsuka M, Yoshikawa T, Kishikawa T, Ohno M, Koike K. MicroRNAs and liver function. Minerva Gastroenterol Dietol 2013;59:187.
18. Pauley KM, Chan EK. MicroRNAs and their emerging roles in immunology. Ann N Y Acad Sci 2008;1143:226.
19. Baghy K, Iozzo RV, Kovalszky I. Decorin-TGF-B axis in hepatic fibrosis and cirrhosis. J Histochem Cytochem 2012;60: 262.
20. Dooley S, ten Dijke P. TGF-β in progression of liver disease. Cell Tissue Res 2012;347:245.
21. Inagaki Y, Okazaki I. Emerging insights into transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 2007;56:284.
22. Carpino G, Renzi A, Onori P, Gaudio E. Role of hepatic progenitor cells in nonalcoholic fatty liver disease development: cellular cross-talks and molecular networks. Int J Mol Sci 2013;14:20112.
23. Lade A, Noon LA, Friedman SL. Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr Opin Oncol 2014;26:100.
24. Chavez-Tapia NC, Rosso N, Tiribelli C. Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease. BMC Gastroenterol 2012;12:20.
25. Yang L, Roh YS, Song J, et al. Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism. Hepatology; 2013. http://dx.doi.org/10.1002/hep.26698.
26. Deng ZB, Poliakov A, Hardy RW, et al. Adipose tissue exosome-like vesicles mediate activation of macrophage-induced insulin resistance. Diabetes 2009;58:2498.
27. Lässer C, Alikhani VS, Ekström K, et al. Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages. J Transl Med 2011;9:9.
28. Chiba M, Kimura M, Asari S. Exosomes secreted from human colorectal cancer cell lines contain mRNAs, microRNAs and natural antisense RNAs, that can transfer into the human hepatoma HepG2 and lung cancer A549 cell lines. Oncol Rep 2012;28:1551.
29. Kogure T, Yan IK, Lin WL, Patel T. Extracellular vesicle-mediated transfer of a novel long noncoding RNA TUC339: a mechanism of intercellular signaling in human hepatocellular cancer. Genes Cancer 2013;4:261.
30. Ramachandran P, Iredale JP. Liver fibrosis: a bidirectional model of fibrogenesis and resolution. QJM 2012;105:813.
31. Iredale JP, Benyon RC, Arthur MJ, et al. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology 1996;24: 176.
32. Han YP. Matrix metalloproteinases, the pros and cons, in liver fibrosis. J Gastroenterol Hepatol 2006;21(Suppl 3):S88.
33. Asselah T, Bièche I, Laurendeau I, et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 2005;129:2064.
34. Qin L, Han YP. Epigenetic repression of matrix metalloproteinases in myofibroblastic hepatic stellate cells through histone deacetylases 4: implication in tissue fibrosis. Am J Pathol 2010;177:1915.
35. Richards TJ, Park C, Chen Y, et al. Allele-specific transactivation of matrix metalloproteinase 7 by FOXA2 and correlation with plasma levels in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012;302:L746.
36. Piotrowski WJ, Górski P, Pietras T, Fendler W, Szemraj J. The selected genetic polymorphisms of metalloproteinases MMP2, 7, 9 and MMP inhibitor TIMP2 in sarcoidosis. Med Sci Monit 2011;17:CR598.
37. Moinzadeh P, Krieg T, Hellmich M, et al. Elevated MMP-7 levels in patients with systemic sclerosis: correlation with pulmonary involvement. Exp Dermatol 2011;20:770.
38. Nadler EP, Patterson D, Violette S, et al. Integrin alphavbeta6 andmediators of extracellularmatrix deposition are upregulated in experimental biliary atresia. J Surg Res 2009;154:21.
39. Beier JI, Arteel GE. Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism. Exp Biol Med (Maywood) 2012;237:1.
40. Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. J Cell Physiol 2012;227:493.
41. Wang H, Zhang Y, Heuckeroth RO. PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA. FEBS Lett 2007;581:3098.
42. van der Flier A, Sonnenberg A. Function and interactions of integrins. Cell Tissue Res 2001;305:285.
43. Tatler AL, John AE, Jolly L, et al. Integrin αvβ5-mediated TGF-β activation by airway smooth muscle cells in asthma. J Immunol 2011;187:6094.
44. Matsumoto N, Ishimura E, Koyama H, et al. Blocking of alpha 5 integrin stimulates production of TGF-beta and PAI-1 by human mesangial cells. Biochem Biophys Res Commun 2003; 305:815.
45. Patsenker E, Stickel F. Role of integrins in fibrosing liver diseases. Am J Physiol Gastrointest Liver Physiol 2011;301: G425.
46. Iordanskaia T, Hubal MJ, Koeck E, Rossi C, Schwarz K, Nadler EP. Dysregulation of upstream and downstream transforming growth factor-β transcripts in livers of children with biliary atresia and fibrogenic gene signatures. J Pediatr Surg 2013;48:2047.
47. Nadler EP, Patterson D, Violette S, et al. Integrin alphavbeta6 andmediators of extracellularmatrix deposition are upregulated in experimental biliary atresia. J Surg Res 2009;154:21.
48. Wajchenberg BL, Nery M, Cunha MR, Silva ME. Adipose tissue at the crossroads in the development of the metabolic syndrome, inflammation and atherosclerosis. Arq Bras Endocrinol Metabol 2009;53:145.
49. Verrecchia F, Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 2002;118:211.
50. Lee JH, Lee H, Joung YK, et al. The use of low molecular weight heparin-pluronic nanogels to impede liver fibrosis by inhibition the TGF-β/Smad signaling pathway. Biomaterials 2011;32:1438.